Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Padagis Launches First-To-Market Zomig Nasal Spray Ahead Of Lannett

Follows Recent Deal With Sol-Gel For Rights Related To 10 Collaborative Agreements

Executive Summary

Less than six months into life as an independent company, former Perrigo Rx unit Padagis has realized its second generic launch, with the first-to-market entry of generic Zomig (zolmitriptan) nasal spray.

You may also be interested in...



Perrigo Suffers As It Waves Goodbye To Rx

Perrigo CEO Murray Kessler has acknowledged “disappointing” third quarter results for the company during a transitional quarter that saw it finally divest its Rx prescription generics business ahead of its upcoming acquisition of consumer healthcare specialist HRA Pharma.

Padagis Starts Life Post-Perrigo With Eucrisa Challenge

Padagis, the former Perrigo Rx business that was acquired by Altaris in July, has seen litigation initiated by Eucrisa originator Anacor over its Paragraph IV ANDA filing for crisaborole 2% ointment.

Perrigo Reaches $1.5bn Deal With Altaris For Rx Business

Perrigo has finally found the right deal to secure the long-awaited divestment of its prescription business, reaching an agreement worth just over $1.5bn with private equity firm Altaris Capital Partners.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel